Literature DB >> 24226524

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Volker Vallon1, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg.   

Abstract

Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 mg/dl) and prevented glomerular hyperfiltration but did not attenuate albuminuria or renal growth and inflammation. Here we determined effects of the SGLT2 inhibitor empagliflozin (300 mg/kg of diet for 15 wk; corresponding to 60-80 mg·kg(-1)·day(-1)) in type 1 diabetic Akita mice that, opposite to streptozotocin-diabetes, upregulate renal SGLT2 expression. Akita diabetes, empagliflozin, and Akita + empagliflozin similarly increased renal membrane SGLT2 expression (by 38-56%) and reduced the expression of SGLT1 (by 33-37%) vs. vehicle-treated wild-type controls (WT). The diabetes-induced changes in SGLT2/SGLT1 protein expression are expected to enhance the BG-lowering potential of SGLT2 inhibition, and empagliflozin strongly lowered BG in Akita (means of 187-237 vs. 517-535 mg/dl in vehicle group; 100-140 mg/dl in WT). Empagliflozin modestly reduced GFR in WT (250 vs. 306 μl/min) and completely prevented the diabetes-induced increase in glomerular filtration rate (GFR) (255 vs. 397 μl/min). Empagliflozin attenuated increases in kidney weight and urinary albumin/creatinine ratio in Akita in proportion to hyperglycemia. Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption. Empagliflozin attenuated/prevented the increase in systolic blood pressure, glomerular size, and molecular markers of kidney growth, inflammation, and gluconeogenesis in Akita. We propose that SGLT2 inhibition can lower GFR independent of reducing BG (consistent with the tubular hypothesis of diabetic glomerular hyperfiltration), while attenuation of albuminuria, kidney growth, and inflammation in the early diabetic kidney may mostly be secondary to lower BG.

Entities:  

Keywords:  diabetes; diabetic nephropathy; gluconeogenesis; inflammation; phosphoenolpyruvate carboxykinase; proximal tubule; renal growth

Mesh:

Substances:

Year:  2013        PMID: 24226524      PMCID: PMC3920018          DOI: 10.1152/ajprenal.00520.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  45 in total

1.  A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria.

Authors:  Daniella Magen; Eli Sprecher; Israel Zelikovic; Karl Skorecki
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

Review 2.  Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation.

Authors:  P G Quinn; D Yeagley
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2005-12

3.  Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

Authors:  Hassan Rahmoune; Paul W Thompson; Joanna M Ward; Chari D Smith; Guizhu Hong; John Brown
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

4.  On the prognosis of IDDM patients with large kidneys.

Authors:  H J Baumgartl; G Sigl; P Banholzer; M Haslbeck; E Standl
Journal:  Nephrol Dial Transplant       Date:  1998-03       Impact factor: 5.992

5.  Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes.

Authors:  Gianpaolo Zerbini; Riccardo Bonfanti; Franco Meschi; Emilio Bognetti; Pier Luigi Paesano; Luigi Gianolli; Marialuisa Querques; Anna Maestroni; Giliola Calori; Alessandro Del Maschio; Ferruccio Fazio; Livio Luzi; Giuseppe Chiumello
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

6.  High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells.

Authors:  Ho Jae Han; Yun Jung Lee; Su Hyung Park; Jang Hern Lee; Mary Taub
Journal:  Am J Physiol Renal Physiol       Date:  2004-12-14

7.  Fluorescein-labeled sinistrin as marker of glomerular filtration rate.

Authors:  Johannes Pill; Bettina Kraenzlin; Julia Jander; Tim Sattelkau; Maliha Sadick; Hans-Martin Kloetzer; Carsten Deus; Uwe Kraemer; Norbert Gretz
Journal:  Eur J Med Chem       Date:  2005-10       Impact factor: 6.514

8.  Tubular lesions in streptozotocin-diabetic rats.

Authors:  R Rasch
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

9.  Effect of puberty on markers of glomerular hypertrophy and hypertension in IDDM.

Authors:  M L Lawson; E B Sochett; P G Chait; J W Balfe; D Daneman
Journal:  Diabetes       Date:  1996-01       Impact factor: 9.461

10.  Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody.

Authors:  Daniela Balen; Marija Ljubojevic; Davorka Breljak; Hrvoje Brzica; Vilim Zlender; Hermann Koepsell; Ivan Sabolic
Journal:  Am J Physiol Cell Physiol       Date:  2008-06-04       Impact factor: 4.249

View more
  143 in total

1.  Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis.

Authors:  K Melissa Hallow; Yeshitila Gebremichael; Gabriel Helmlinger; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2017-02-01

2.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

3.  Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.

Authors:  Takahiro Masuda; Yuko Watanabe; Keiko Fukuda; Minami Watanabe; Akira Onishi; Ken Ohara; Toshimi Imai; Hermann Koepsell; Shigeaki Muto; Volker Vallon; Daisuke Nagata
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-23

4.  Recent advances in sex differences in kidney function.

Authors:  Anita T Layton; Jennifer C Sullivan
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-19

5.  Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis.

Authors:  Corey B Hughes; George M Mussman; Phil Ray; Robert C Bunn; Virgilius Cornea; Kathryn M Thrailkill; John L Fowlkes; Iuliana Popescu
Journal:  Cell Tissue Res       Date:  2021-01-06       Impact factor: 5.249

6.  Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.

Authors:  T Cooper Woods; Ryousuke Satou; Kayoko Miyata; Akemi Katsurada; Courtney M Dugas; Natasha C Klingenberg; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Nephrol       Date:  2019-03-28       Impact factor: 3.754

Review 7.  Renal effects of dapagliflozin in patients with type 2 diabetes.

Authors:  Merlin C Thomas
Journal:  Ther Adv Endocrinol Metab       Date:  2014-06       Impact factor: 3.565

8.  Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model.

Authors:  Blythe D Shepard; Hermann Koepsell; Jennifer L Pluznick
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-28

Review 9.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

Review 10.  Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update.

Authors:  Aleksandra Novikov; Volker Vallon
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.